Products - Antigen detection - Therap. drug monitoring of Biologics - TNF-Alpha Inhibitors

TNF-α inhibitors

Contact our Antigen Product Team for further details and information

Disease information

TNF-Alpha is a primary mediator in many chronic inflammatory conditions such as rheumatoid arthritis, chronic inflammatory bowel disease, psoriasis etc. Recognition of its role in bringing about inflammation has led to a new, targeted approach towards treating such conditions. Now, specific TNF-Alpha inhibitors are used to counter act the effects of this mediator of inflammation and reverse the condition. Such drugs represent a subgroup called biologics (technologically produced drugs of biologic origin). Most of these drugs have two active ingredients: adalimumab and infliximab.

During the course of treatment with these drugs, the active ingredient is continuously increased initially until the point where an optimal status and significant improvement in the symptoms is achieved. Thereafter an increase in the active ingredient will only lead to side effects. To determine the proper doses, individual specific pharmacokinetics and dynamics are applied and the drugs levels are constantly monitored from the start of the therapy.

A common problem that occurs with the use of these drugs is the formation of anti-drug antibodies. Hence, ADA estimations are necessary for making any therapeutic adjustments in cases of drug resistance.

Diagnostic Guidelines

The most effective therapeutic approach with biologics is to constantly monitor drug levels for individualized and cost-effective patient management. Good thing, EUROIMMUN is the official distributor of Sanquin Reagents. We offer Mab Track Level ELISA (from Sanquin Reagents) for specific determination of adalimumab and infliximab concentrations. It also allows for the estimation of anti-drug antibody levels that often develop and result in treatment failure. Thus, Mab Track ELISA can be used to monitor drug levels and correlate them with the clinical picture of the patient to comprehensively assess success of the therapy and make any adjustments, if required.

TNF-α inhibitors products

The individual product regulatory statements may vary, please refer to the instructions for use for more information.

wdt_ID Method Parameter
568 ELISA MabTrack level adalimumab
569 ELISA MabTrack anti-drug antibody adalimumab
570 ELISA MabTrack level infliximab
571 ELISA MabTrack anti-drug antibody infliximab
Method Parameter
For product information, please contact the EUROIMMUN Sales Team

Product Catalog

Download our full EUROIMMUN US 2022 Product Catalog (PDF 12MB)

Download PDF

2022 EUROIMMUN US

Privacy Policy | Sitemap